Your browser doesn't support javascript.
loading
Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myeloma.
Bohl, Stephan R; Schmalbrock, Laura K; Bauhuf, Imke; Meyer, Tatjana; Dolnik, Anna; Szyska, Martin; Blätte, Tamara J; Knödler, Sarah; Röhner, Linda; Miller, Denise; Kull, Miriam; Langer, Christian; Döhner, Hartmut; Letai, Anthony; Damm, Frederik; Heckl, Dirk; Bullinger, Lars; Krönke, Jan.
Afiliação
  • Bohl SR; Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany.
  • Schmalbrock LK; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Bauhuf I; Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany.
  • Meyer T; Department of Hematology, Oncology and Tumor Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Dolnik A; Berlin Institute of Health at Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Szyska M; Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany.
  • Blätte TJ; Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany.
  • Knödler S; Department of Hematology, Oncology and Tumor Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Röhner L; Department of Hematology, Oncology and Tumor Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Miller D; Department of Hematology, Oncology and Tumor Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Kull M; Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany.
  • Langer C; Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany.
  • Döhner H; Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany.
  • Letai A; Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany.
  • Damm F; Department of Hematology, Internal Oncology and Palliative Care, Kempten Hospital, Kempten, Germany; and.
  • Heckl D; Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany.
  • Bullinger L; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Krönke J; Department of Hematology, Oncology and Tumor Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Blood Adv ; 5(9): 2391-2402, 2021 05 11.
Article em En | MEDLINE | ID: mdl-33950175
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Preparações Farmacêuticas / Mieloma Múltiplo Limite: Humans Idioma: En Revista: Blood Adv Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Alemanha
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Preparações Farmacêuticas / Mieloma Múltiplo Limite: Humans Idioma: En Revista: Blood Adv Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Alemanha